Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Clinical trial NCT04040361 · UNKNOWN

Trial details

NCT number: NCT04040361
Sponsor: Masahiro Tsuboi
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Stage IB Non-small Cell Lung Cancer Stage II Non-small Cell Lung Cancer Stage ⅢA

Start date: 2019-11-30
Primary completion: 2022-04-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.